CJC-1295 / Ipamorelin tracker
for iPhone.
CJC-1295 paired with Ipamorelin is the canonical GH-axis stack — a slow GHRH plus a clean GHRP, often co-reconstituted in one vial and dosed nightly before bed. The math gets fiddly fast: two compounds, two doses, one syringe, one timing window. Peptide Protocol treats the blend as a single first-class object so you set the per-peptide dose once and the calculator does the split.
Download Peptide Protocol — FreeCJC-1295 / Ipamorelin at a glance
Quick reference for the protocol-builder. CJC-1295 comes in two variants — with DAC (long half-life) and without DAC, sometimes called "Mod GRF (1-29)" (short half-life). The app supports both.
| Class | GHRH analog (CJC-1295) + GHRP / ghrelin mimetic (Ipamorelin) — additive GH release |
|---|---|
| Brand names | None — both are research peptides; not FDA-approved for any indication |
| Half-life — CJC-1295 | With DAC: 6–8 days. Without DAC ("Mod GRF 1-29"): ~30 minutes. |
| Half-life — Ipamorelin | ~2 hours |
| Typical cadence | No-DAC variant: nightly (sometimes BID for advanced protocols). With-DAC: 1–2× weekly. |
| Typical per-dose targets | CJC-1295: 100 µg. Ipamorelin: 200–300 µg. Often combined in a single draw. |
| Common reconstitution | 2 mg CJC-1295 + 5 mg Ipamorelin co-vialled in 3 mL BAC water → 0.67 mg/mL CJC + 1.67 mg/mL Ipa |
| Insulin syringe | U-100 (15 units = 0.15 mL → 100 µg CJC + 250 µg Ipa at the above concentration) |
| Cycle length | 8–12 weeks on, 4 weeks off is the most cited self-protocol pattern; longer continuous use is debated |
For full mechanism, GH-pulse literature, and the with-DAC vs no-DAC discussion, see the CJC-1295 / Ipamorelin guide on peptide-calc.app.
Built around CJC / Ipa protocols
Three things blend protocols actually need.
Blend-aware math
Define your vial as a blend with two compounds and two masses. Set per-peptide dose targets. The calculator returns the single unit count that delivers both — no spreadsheet, no second draw.
Pre-bed reminder, widget-first
Nightly cadence lives or dies by timing. Pin a widget to your home screen with the next dose time and a one-tap "Done" button. The app sends a gentle reminder; the widget keeps the window visible.
GH-axis stack support
If you layer Tesamorelin, MK-677, or BPC-157 on top, the Today screen shows the full stack with rotation, cadence, and inventory all separated. No double-draws, no mixed timing.
What it looks like
CJC-1295 / Ipamorelin — common questions
Does Peptide Protocol handle the CJC / Ipa blend in one vial?
Yes. Blends are first-class. Define one vial with both peptides and their respective masses (e.g., 2 mg CJC-1295 + 5 mg Ipamorelin in 3 mL BAC water). The calculator splits the per-compound dose automatically — set 100 µg CJC + 250 µg Ipamorelin and it tells you the single unit count for both at once.
CJC-1295 with DAC versus without — does the app track both?
Yes. Both are calculator presets. With-DAC has a long half-life (6–8 days) and is typically dosed once or twice weekly. No-DAC has a short half-life (~30 minutes) and is typically dosed nightly, often paired with Ipamorelin in the same draw. Choose the variant in the protocol-builder and the schedule and reminder cadence follow.
When should I dose CJC-1295 / Ipamorelin?
The most cited timing is nightly, 2–3 hours after the last meal and just before sleep, to land the GH pulse in the early-night window. The app will send a gentle reminder at the time you choose, plus widget surfaces on the home screen so you don't miss the pre-bed window.
Related peptide trackers
Track your GH-axis stack on your iPhone.
Free on the App Store. Builds your first protocol in under five minutes. No account required.
Download on the App StoreNot medical advice. CJC-1295 and Ipamorelin are research peptides. Neither is FDA-approved for any human indication and both are restricted under WADA in competition. The information on this page is informational and does not constitute a recommendation to use the compounds. Always consult a licensed healthcare professional before starting, modifying, or stopping any compound. See the full reference for primary sources.